

IPAR



**Publicly Available Assessment Report for a
Veterinary Medicinal Product**

Synulox Ready-To-Use Injection

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Synulox Ready to Use Injection, 100 ml
Active substance(s)	Amoxicillin trihydrate Potassium clavulanate
Marketing Authorisation Holder	Zoetis Belgium S.A. 2nd Floor, Building 10, Cherrywood Business Park, Loughlinstown, Co. Dublin, Ireland
Legal basis of application	Full application in accordance with Article 12(3) of Directive 2001/82/EC as amended.
Date of Authorisation	01/10/1997
Target species	Cattle, pigs, dogs and cats.
Indication for use	Indicated for the treatment of diseases including: Cattle; Respiratory infections, soft tissue infections (e.g. joint-ill/navel-ill, abscesses etc.), metritis and mastitis. Pigs; Respiratory bacterial infections in growing pigs; Colibacillosis, Periparturient infections in sows (e.g. mastitis, metritis and agalactia). Dogs and Cats; Respiratory tract infections, urinary tract infections and skin and soft tissue infections (e.g.

	abscesses, pyoderma, anal sacculitis, gingivitis).
ATCvet code	QJ01CR02

PUBLIC ASSESSMENT REPORT

The Public Assessment Report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by HPRA leading to the approval of the product for marketing in Ireland.

I. SCIENTIFIC OVERVIEW

The initial application for Synulox Ready to Use Injection, 100 ml was assessed before there was a requirement to have a public assessment report, therefore no details in this section are available. Please refer to section VI for significant post-approval changes which are important for the quality, safety and efficacy of the product.

II. QUALITY ASPECTS

See section I.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

See section I.

IV. CLINICAL ASSESSMENT

See section I.

V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

On the basis of the original data submitted, the HPRA considered that Synulox Ready to Use Injection, 100 ml demonstrated adequate evidence of efficacy for the approved indications as well as a satisfactory benefit/risk profile and therefore granted a marketing authorisation.

VI. POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the HPRA website.

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Safety/Efficacy Changes

Summary of change	Approval date
Addition of target species adverse reaction Type IB C.1.3.a) variation to include additional safety warnings. HPRA case reference number 7008305	17 th November 2010